Oxytocin receptor knockdown reduces the viability of glioma cells [115], neurotensin 1 receptor knockdown suppresses the growth and invasion of these cells [54], and the silencing of the truncated splicing variant of the somatostatin 5 receptor sensitizes glioblastoma cells to the antitumor action exerted by the somatostatin analog pasireotide [103]. This evidence concerns the gene NTSR1 and central nervous system cancer.